Health Complications Cited After 50 of MiMedx’s Graft Treatments
- Biotech firm says its incident reporting complies with rules
- Inflammation, infection and a toe amputation in 4 FDA filings
This article is for subscribers only.
Biotech firm MiMedx Group Inc. has assured the public that its tissue grafts are safe, causing zero complications for patients, as it faces down federal investigations and short sellers.
Now that depiction is growing cloudy.